Carboplatin

Generic Name: Carboplatin

Brand Names: Paraplatin

Drug Type: Small Molecule

Chemical Formula: C_₆H_₁₂N_₂O_₄Pt

CAS Number: 41575-94-4

Unique Ingredient Identifier: BG3F62OND5

Background: Carboplatin is an organoplatinum antineoplastic alkylating agent used in the treatment of advanced ovarian carcinoma. Early clinical studies of carboplatin were performed in 1982. Carboplatin was developed as an analog of cisplatin with reduced nephrotoxicity and vomiting.

Carboplatin was granted FDA approval on 3 March 1989.

Indication: Carboplatin is indicated in combination with an established combination of chemotherapeutic agents for the initial treatment of advanced ovarian carcinoma. Carboplatin is also indicated for the palliative treatment of ovarian carcinoma, recurrent after prior chemotherapy.

Associated Conditions: Advanced Cervical Cancer, Advanced Endometrial Cancer, Advanced Esophageal Cancers, Advanced Head and Neck Cancer, Advanced Melanoma, Advanced Non-Small Cell Lung Cancer (NSCLC), Advanced Ovarian Carcinoma, Advanced Sarcoma, Malignant Pleural Mesothelioma (MPM), Merkel Cell Carcinoma, Metastatic Breast Cancer, Refractory Hodgkin Lymphoma, Retinoblastoma, Thymoma, Advanced Bladder cancer, Advanced Small cell lung cancer, Advanced Testicular cancer, Advanced Thymoma, Refractory Non-Hodgkin's lymphoma

Associated Therapies: Conditioning regimens for allogeneic stem cell transplantation therapy

Clinical Trials

Paclitaxel and Carboplatin With or Without Nitroglycerin in Treating Patients With Previously Untreated Stage III or Stage IV Non-Small Cell Lung Cancer

Phase 2

Conditions: Lung Cancer

First Posted Date: 2008-02-15

Last Posted Date: 2013-08-12

Lead Sponsor: Kyoto University

Target Recruit Count: 150

Registration Number: NCT00616031

Locations: 🇯🇵
Kyoto University Hospital, Kyoto, Japan

Chemotherapy and Proton Radiation for the Treatment of Locally Advanced Lung Cancer

Phase 1

Terminated

Conditions: Locally Advanced Non-Small Cell Lung Cancer

Interventions: Radiation: Proton Radiation Therapy
Drug: Taxol
Drug: Carboplatin

First Posted Date: 2008-02-13

Last Posted Date: 2014-05-22

Lead Sponsor: Loma Linda University

Target Recruit Count: 28

Registration Number: NCT00614484

Locations: 🇺🇸
Loma Linda University Medical Center, Loma Linda, California, United States

AZD0530 Phase II Study in Patients With Advanced Ovarian Cancer

Phase 2

Completed

Conditions: Ovarian Neoplasms
Ovarian Cancer

Interventions: Drug: AZD0530
Drug: Carboplatin
Drug: Paclitaxel

First Posted Date: 2008-02-08

Last Posted Date: 2012-12-18

Lead Sponsor: AstraZeneca

Target Recruit Count: 211

Registration Number: NCT00610714

Locations: 🇬🇧
Research Site, Coventry, United Kingdom

Phase II Trial of Doxil, Carboplatin, Bevacizumab in Triple Negative Untreated Metastatic Breast Cancer

Phase 2

Completed

Conditions: Metastatic Breast Cancer

Interventions: Drug: Doxil
Drug: Carboplatin
Drug: Bevacizumab

First Posted Date: 2008-02-06

Last Posted Date: 2023-02-08

Lead Sponsor: Rutgers, The State University of New Jersey

Target Recruit Count: 31

Registration Number: NCT00608972

Locations: 🇺🇸
Saint Peter's University Hospital, New Brunswick, New Jersey, United States
🇺🇸
Jersey Shore University Medical Center, Neptune, New Jersey, United States
🇺🇸
Cooper Hospital/University Medical Center, Camden, New Jersey, United States

and more 4 locations

Vorinostat, Rituximab, Ifosfamide, Carboplatin, and Etoposide in Treating Patients With Relapsed or Refractory Lymphoma or Previously Untreated T-Cell Non-Hodgkin Lymphoma or Mantle Cell Lymphoma

Phase 1

Completed

Conditions: Recurrent Adult Diffuse Large Cell Lymphoma
Recurrent Adult Diffuse Mixed Cell Lymphoma
Recurrent Adult Diffuse Small Cleaved Cell Lymphoma
Recurrent Adult Grade III Lymphomatoid Granulomatosis
Recurrent Adult Hodgkin Lymphoma
Recurrent Adult Immunoblastic Large Cell Lymphoma
Recurrent Adult Lymphoblastic Lymphoma
Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma
Recurrent Grade 1 Follicular Lymphoma
Recurrent Grade 2 Follicular Lymphoma

Interventions: Drug: vorinostat
Biological: rituximab
Drug: ifosfamide
Drug: carboplatin
Drug: etoposide
Other: pharmacological study
Other: laboratory biomarker analysis
Genetic: gene expression analysis

First Posted Date: 2008-01-28

Last Posted Date: 2017-05-25

Lead Sponsor: University of Washington

Target Recruit Count: 29

Registration Number: NCT00601718

Locations: 🇺🇸
Puget Sound Oncology Consortium, Seattle, Washington, United States

A Study Of AG-013736 (Axitinib) Or Bevacizumab (Avastin) In Combination With Paclitaxel And Carboplatin In Patients With Advanced Lung Cancer.

Phase 2

Completed

Conditions: Non-Small-Cell Lung Carcinoma
Adenocarcinoma

Interventions: Drug: Bevacizumab
Drug: AG-013736 (axitinib)
Drug: Carboplatin
Drug: Paclitaxel

First Posted Date: 2008-01-25

Last Posted Date: 2013-11-08

Lead Sponsor: Pfizer

Target Recruit Count: 118

Registration Number: NCT00600821

Locations: 🇬🇧
Pfizer Investigational Site, Surrey, United Kingdom

Neoadjuvant Bevacizumab and Carboplatin Followed by Concurrent Bevacizumab, Carboplatin and Radiotherapy in the Primary Treatment of Cervix Cancer

Phase 2

Withdrawn

Conditions: Cervical Cancer

Interventions: Drug: Bevacizumab
Drug: Carboplatin
Radiation: Radiation Therapy

First Posted Date: 2008-01-24

Last Posted Date: 2017-08-23

Lead Sponsor: Leo W. Jenkins Cancer Center

Registration Number: NCT00600210

Locations: 🇺🇸
East Carolina University School of Medicine, Greenville, North Carolina, United States

Bortezomib, Ifosfamide, Carboplatin, and Etoposide, With or Without Rituximab, in Treating Patients With Relapsed or Refractory AIDS-Related Non-Hodgkin Lymphoma

Phase 1

Completed

Conditions: Lymphoma

Interventions: Biological: rituximab
Drug: bortezomib
Drug: carboplatin
Drug: dexamethasone
Drug: etoposide
Drug: ifosfamide
Genetic: polymerase chain reaction
Genetic: western blotting

First Posted Date: 2008-01-18

Last Posted Date: 2020-08-10

Lead Sponsor: AIDS Malignancy Consortium

Target Recruit Count: 23

Registration Number: NCT00598169

Locations: 🇺🇸
Emory Winship Cancer Institute, Atlanta, Georgia, United States
🇺🇸
Baylor College of Medicine, Houston, Texas, United States
🇺🇸
UCLA Clinical AIDS Research and Education (CARE) Center, Los Angeles, California, United States

and more 14 locations